Skip to main content
Premium Trial:

Request an Annual Quote

Thallion Sells Stake in Caprion for $4.5M

NEW YORK (GenomeWeb News) – Thallion Pharmaceuticals today said that it has sold its remaining stake in Caprion Proteomics for approximately C$4.5 million (US$4.5 million).

The Montreal-based proteomics firm was sold by healthcare investment firm Great Point Partners to an affiliate of Chicago Growth Partners. The sale comes four years after Thallion sold an 80 percent interest in Caprion to Great Point.

Thallion today said that it received approximately C$3.9 million for its remaining stake in Caprion, and it will receive further cash proceeds within the next 15 months of up to C$583,000 which is currently being held in escrow.

Thallion also is entitled to a pro rata share of net proceeds generated from the licensing, selling, or commercialization of diagnostic products or services using certain Caprion products.

Caprion provides biomarker services using its CellCarta and multiplexed multiple reaction monitoring assays as well as diagnostic development services.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.